Results 261 to 270 of about 229,722 (383)
Direct-to-Consumer Erectile Dysfunction Medications: is the Convenience Worth the Cost? [PDF]
Li MK, Patel DP, Hsieh TC.
europepmc +1 more source
We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp +5 more
wiley +1 more source
RETRACTION: Ligustrazine Inhibits Lung Phosphodiesterase Activity in a Rat Model of Allergic Asthma. [PDF]
And Mathematical Methods In Medicine C.
europepmc +1 more source
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui +15 more
wiley +1 more source
Intercellular diffusion of cyclic nucleotides followed by gap junction closure restarts meiosis in mouse preovulatory follicles. [PDF]
Nakashima IF +6 more
europepmc +1 more source
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault +51 more
wiley +1 more source
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics
Euikyung Kim +7 more
openalex +1 more source
Engineering the bacterial nutrition strategy to control plant diseases
This commentary on Wang et al. (2025) and Phan et al. (2025) highlights previously undiscovered Xanthomonas pathways for nutrition acquisition, explains how Xanthomonas bacteria hijack host molecular machinery through their effector proteins, and discusses how these studies can be used to develop new disease resistance mechanisms.
Muhammad Arslan Mahmood +2 more
wiley +1 more source

